# Enthera Pharmaceuticals

> Enthera Pharmaceuticals is a clinical-stage biotech based in Milan, Italy, developing first-in-class biologics that aim to do something most autoimmune drugs do not: restore the organ, not just calm the inflammation. Its lead antibody, ebrasodebart (Ent001), blocks the IGFBP3/TMEM219 pathway, a signal that drives apoptosis of intestinal stem cells in the gut and insulin-producing beta cells in the pancreas. The company targets inflammatory bowel disease and type 1 diabetes, two conditions with deep unmet need, and is advancing the program through Phase 1 clinical trials.

- **Founded:** 2016
- **Headquarters:** Milan, Italy
- **Founders:** Paolo Fiorina (Scientific Co-Founder & Chief Scientific Officer), Francesca D'Addio (Scientific Co-Founder)
- **Team size:** Approximately 11 employees
- **Products:** Ebrasodebart (Ent001), IGFBP3/TMEM219 platform
- **Notable:** Raised €28 million in 2020 - reported as the largest international VC-backed Series A for biotech in Italy at the time, First spin-off of BiovelocITA, Italy's first biotech accelerator, Advanced lead candidate ebrasodebart (Ent001) into Phase 1 clinical trials

## Products & services

- **Ebrasodebart (Ent001)** — Lead first-in-class monoclonal antibody targeting the IGFBP3/TMEM219 pathway. By blocking the apoptotic signal that destroys colonic stem cells and pancreatic beta cells, it aims to restore intestinal mucosal structure in IBD and the endogenous pancreatic stem cell compartment in type 1 diabetes. Currently in Phase 1 clinical development, including a Phase 1b proof-of-concept trial in ulcerative colitis.
- **IGFBP3/TMEM219 platform** — A discovery engine built around the IGFBP3/TMEM219 axis - a pathway in which elevated IGFBP3 binds the TMEM219 receptor and triggers apoptosis of stem and organ cells in the gut and pancreas. The platform supports antibodies and fusion proteins across multiple autoimmune indications.

## Achievements

- Raised €28 million in 2020 - reported as the largest international VC-backed Series A for biotech in Italy at the time
- First spin-off of BiovelocITA, Italy's first biotech accelerator
- Advanced lead candidate ebrasodebart (Ent001) into Phase 1 clinical trials
- Completed patient enrollment in a Phase 1b proof-of-concept trial in ulcerative colitis
- Published pathway research in Nature Communications and The Journal of Clinical Investigation
- Attracted strategic investment from AbbVie and the JDRF T1D Fund

## Latest updates

- **2025-05** — Announced publication in The Journal of Clinical Investigation revealing TMEM219's role in driving intestinal stem cell apoptosis and impairing mucosal healing in IBD, supporting the clinical development of ebrasodebart.
- **2024-03** — Presented preclinical data on Ent001, an anti-TMEM219 antibody for ulcerative colitis, at the European Crohn's and Colitis Organization (ECCO) annual meeting.
- **2024-01** — Appointed Lisa M. Olson, Ph.D., as Chief Executive Officer and reported clinical trial progress with Ent001.
- **2023-03** — Initiated a Phase 1 clinical trial with lead candidate Ent001.
- **2020-07** — Raised €28 million in Series A financing co-led by Sofinnova Partners and AbbVie.

## Links

- Website: https://www.entherapharmaceuticals.com
- LinkedIn: https://www.linkedin.com/company/enthera-pharmaceuticals

---

Profile page: https://yespress.io/enthera-pharmaceuticals
Published by YesPress — https://yespress.io
Last updated: 2026-06-15